Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
The comparators presented in Table 6 have been deemed appropriate by the clinical expert consulted by the CADTH Common Drug Review. Costs are manufacturer list prices, unless otherwise specified. Existing product reimbursement agreements are not reflected in the table and as such may not represent the actual costs to public drug plans.
- COST COMPARISON - Edoxaban (Lixiana)COST COMPARISON - Edoxaban (Lixiana)
- REVIEWER WORKSHEETS - Edoxaban (Lixiana)REVIEWER WORKSHEETS - Edoxaban (Lixiana)
- CONCLUSIONS - Ingenol Mebutate (Picato)CONCLUSIONS - Ingenol Mebutate (Picato)
- LIMITATIONS OF MANUFACTURER’S SUBMISSION - Edoxaban (Lixiana)LIMITATIONS OF MANUFACTURER’S SUBMISSION - Edoxaban (Lixiana)
Your browsing activity is empty.
Activity recording is turned off.
See more...